Active Portfolio


Our investment portfolio includes companies passionate about the development and commercialization of innovative products and platform technologies for the prevention, diagnosis and treatment of significant diseases.

f-star GmbH

f-star is a biotherapeutics platform company developing next generation antibodies (Ab) and Ab fragments. Their core technology allows the introduction of antigen binding sites into non-CDR loops of Abs, enabling high affinity target binding by Fc fragments or the addition of new binding sites into full length Abs to create bi-specific molecules. f-star is located in Vienna, Austria and Cambridge, UK. MPH participated in f-star’s Extended Series A financing round in January 2010. For more information, please visit

FORGE Therapeutics

Forge Therapeutics is using a novel drug discovery platform to identify and develop first-in-class therapeutics against metalloprotein drug targets.
Their lead program is a non-hydroxamate inhibitor of LpxC, for the treatment of life-threatening gram negative bacterial infections. Forge is based in San Diego, CA. MPH participated in Forge's Series A financing round in April 2017. For more information, please visit .


GenKyoTex is a leader in the development of novel therapeutics targeting Nicotinamide-adenine dinucleotide phosphate (NADPH) oxidases, also called NOX enzymes. GenKyoTex has developed a unique screening platform to identify selective, first in class, novel NOX inhibitors with the potential to treat disease areas with a high clinical need and large market potential. These include diabetes, cardiovascular, neurodegenerative and pulmonary diseases. The lead compound, GKT137831, is a selective NOX1/4 inhibitor that will enter Phase 1 trials later in 2011 and is targeted for the treatment of diabetic nephropathy. MPH participated in the Series C financing round in May 2011. For more information please visit


miRagen Therapeutics is a biopharmaceutical company focused on the discovery and development of innovative microRNA (miRNA)-targeting therapies in disease areas of high unmet medical need. Their lead program is a pro-miR for miR-29 in Phase 1 testing for fibrosis. miRagen has additional programs in cancer, cardiovascular disease and ALS. miRagen is based in Boulder, CO. MPH participated in miRagen's Series C financing round in November 2015. For more information, please visit


Pronota NV is a Belgian diagnostics company with two cutting-edge technologies for low abundance protein biomarker discovery and antibody-free, multiple protein assay development. MPH participated in Pronota's Series B financing round in October 2009. Pronota merged with a division of Biocartis in September 2014 to form MyCartis. For more information, please visit


Rigontec is a biopharmaceutical company targeting RIC-I for the immune-mediated treatment of cancer and viral diseases. MPH participated in Rigontec's Series A financing round in August 2015. Rigontec is based in Bonn, Germany. For more information, please visit


Thrasos Therapeutics is a clinical-stage biotherapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of kidney disease. The company is advancing therapeutic programs, led by THR-184, for renal diseases, including acute kidney injury (AKI) and chronic kidney disease (CKD). MPH participated in Thrasos’ Series C financing round in October 2012. For more information, please visit